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Age and sex differences in the incidence of gastrointestinal cancers
suggest the involvement of sex steroids. Specifically, post-
menopausal loss of oestrogens in women appears to be associated
with a lower risk of colonic cancer (Langman, 1967; Michael and
Potter, 1982). These observations have been supported by studies in
vitro which have highlighted the ability of active oestrogen (oestra-
diol, E2) to stimulate the growth of colonic cancer cell lines (Xu and
Thomas, 1994; Di Domenico et al, 1996). In spite of this, the
precise mechanism by which oestrogens influence colonic cancer
in vivo remains unclear, principally because of conflicting reports
concerning the role and expression of receptors for E2 (oestrogen
receptors, ER) as determinants of oestrogen responsiveness in the
colon (Francavilla et al, 1987; Jacobs et al, 1996). Di Domenico
and colleagues suggested that the oestrogen-dependent growth of
colonic cancer cells in vitro is dependent on ER expression (Di
Domenico et al, 1996). However, although we have previously
demonstrated differential responses to E2 in pre-malignant and
malignant cell lines (Singh et al, 1994), we were unable to correlate
this with differences in ER expression (Singh et al, 1994, 1998). A
further paradox is provided by epidemiological data which show
that hormone replacement therapy (HRT) is associated with a lower
risk of colonic cancer (Calle et al, 1995; Newcomb and Storer,
1995; Persson et al, 1996), although this may reflect differences in
the composition and route of administration of HRT regimes.
To clarify these observations we have carried out a series of
investigations that have focused on the concept of ‘pre-receptor
regulation’ as the principal determinant of oestrogen responsive-
ness in the colon. Analogous to well documented studies in breast
cancer (O’Neill et al, 1988; Sasano et al, 1996), we have postu-
lated that local steroid metabolism in the colon may play a key role
in modulating the effects of oestrogens by determining the tissue
availability of active E2. In recent studies using tissue biopsies we
have shown that the normal colonic mucosa has a high capacity for
metabolism of E2 (English et al, 1999). Furthermore, the predomi-
nant metabolic activity, inactivation of E2 to oestrone (E1), was
significantly decreased in paired tumour biopsies. Conversion of
E2 to E1 is catalysed by the enzyme 17β-hydroxysteroid dehydro-
genase (17β-HSD) for which several isozymes have been identi-
fied (Peltoketo et al, 1999). The presence of 17β-HSD activity in
the colon appears to be due to expression of the type 2 and 4
isozymes of 17β-HSD (17β-HSD2 and 4), and expression of
mRNA for the latter was shown to be significantly decreased in
tumours compared to normal mucosae. In this report we have used
in vitro model systems and tissue analysis in situ to examine
further the relationship between 17β-HSD expression, colonic cell
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Summary Epidemiological data suggest that oestrogen contributes to the aetiology of colonic cancer. Furthermore, recent studies have
suggested that local hormone metabolism may play a key role in determining colonic responsiveness to oestrogen. To further clarify this
mechanism we have characterized the expression and regulation of isozymes of 17β-hydroxysteroid dehydrogenase (17β-HSD) in vitro and
in situ. Immunohistochemistry was used to confirm expression of the type 2 and 4 isozymes of 17β-HSD (17β-HSD2 and 4) in normal colonic
epithelial cells. Parallel studies suggested that both isozymes were abnormally expressed in colonic tumours and this was confirmed by
Western blot analyses. Abnormal expression of 17β-HSD2 and 4 proteins was also observed in Caco-2, HT-29 and SW620 colonic cancer
cell lines, although the overall pattern of oestrogen metabolism in these cells was similar to that seen in primary colonic mucosal tissue. The
predominant activity (conversion of oestradiol to oestrone) was highest in Caco-2>SW620>HT-29, which correlated inversely with the rate of
proliferation of the cell lines. Regulatory studies using SW620 cells indicated that the most potent stimulator of oestradiol to oestrone
inactivation was the antiproliferative agent 1,25-dihydroxyvitamin D3 (1,25D3), whilst oestradiol itself inhibited 17β-HSD activity. Both
oestradiol and 1,25D3 decreased mRNA for 17β-HSD2 and 4. Data indicate that the high capacity for inactivation of oestrogens in the colon
is associated with the presence of 17β-HSD2 and 4 in epithelial cells. Abnormal expression of both isozymes in colonic cancer cells and the
stimulation of oestrogen inactivation by the antiproliferative agent 1,25D3 highlights a possible role for 17β-HSD isozymes as modulators of
colonic cell proliferation. © 2000 Cancer Research Campaign
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proliferation and tumour development. Data provide further
evidence for the importance of 17β-HSD2 and 4 as attenuators of
E2 bioavailability in the colon, and emphasize a possible role for
17β-HSD2 and 4 in the pathogenesis of colon cancer.
ΜΑΤΕΡΙΑΛΣ ΑΝD ΜΕΤΗΟDΣ
Immunohistochemical studies
Colonic tumour and paired normal mucosal tissue were obtained
with agreement from the local ethical approval committee. Five-
micron thick, formalin-fixed tissue sections were cut and placed on
coated glass slides. Sections were de-waxed and endogenous
peroxidase activity quenched with 3% hydrogen peroxide. Sections
were then incubated in donkey serum (Binding Site, Birmingham,
UK) diluted 1/10 in PBS (15 min), followed by primary antibody
diluted in PBS (1 hour). Antisera used were as follows: 17β-HSD2
monoclonal antiserum (1/500 dilution), a kind gift of Dr S
Andersson (South Western Medical Center, Dallas, USA), was
produced with a synthetic carboxyterminal peptide [C]RALRMP-
NYKKKAT, corresponding to amino acids 375–387 in the human
17β-HSD2 protein; 17β-HSD4 monoclonal antibody (1:200 dilu-
tion), a kind gift of Dr J Adamski (GSF, Neuherberg, Germany)
was prepared against the porcine 17β-HSD4 which cross-reacts
with human, rat and mouse tissues. After washing, slides were
incubated for 30 min with a biotinylated universal secondary anti-
body (Binding Site), diluted 1/100 in PBS, and binding visualised
using ABC reagent (Binding Site) and 3,3′-diaminobenzidine
(Sigma Chemical Co, Poole, UK). After staining, slides were
washed and counterstained in Mayer’s haematoxylin.
Cell culture
Colonic carcinoma cell lines (SW620, Caco-2 and HT-29) were
routinely maintained in Dulbecco’s Modified Eagles Medium
(DMEM), supplemented with 5% fetal calf serum (FCS) (both
Life Technologies Ltd, Paisley, UK). Experimental cultures were
carried out using phenol red-free DMEM supplemented with 5%
charcoal-stripped FCS in the presence of absence of treatments
(1–100 nM) which included: E1, E2, progesterone (Prg), dexa-
methasone (DEX), dihydrotestosterone (DHT), testosterone (T)
(all Sigma) and 1α,25-dihydroxyvitamin D3 (a kind gift from Dr M
Uskokovic, Hoffman LaRoche, Nuttley, New Jersey).
Measurement of 17β-HSD activity
Interconversion of E2 to E1 via 17β-HSD was assessed using previ-
ously reported methods (Hughes et al, 1997). Briefly, the substrates
used were 3H-oestradiol (3H-E2) (specific activity: 110 Ci/mmol;
Amersham, Little Chalfont, Buckinghamshire, UK) for measure-
ment of oxidative 17β-HSD activity (E2 to E1), and 3H-oestrone
(3H-E1) (specific activity; 80 Ci/mmol; Amersham) for reductive
activity (E1 to E2). Assays were carried out in triplicate using
substrate concentrations of between 25 nM and 2 µM. Medium was
changed to serum-free DMEM 2 hours prior to enzyme assay and
cells were then incubated in a further aliquot of serum-free medium
containing 3H-E2 or 3H-E1. Reaction mixtures were extracted in
chloroform and then separated on silica thin layer chromatography
(TLC) plates in chloroform:ethyl-acetate (80:20 v/v). Conversion
of tritiated steroid was measured using a Bioscan System 200
imaging TLC plate scanner (Bioscan Inc, Washington DC, USA),
and the fractional conversion of E2 to E1, or E2 to E1 calculated.
Residual cell monolayers were lysed and proteins analysed using
standard Biorad protein assay (Biorad, Hemel Hempstead, UK).
Activity was expressed as pmol product h–1 mg protein–1.
Analysis of cell proliferation
Colonic cells were incubated with 0.5 µCi 3H-thymidine (specific
activity 80 Ci mmol–1; Amersham) for the last 6 hours of culture
incubation. Unlabelled thymidine was added for the last 5 minutes
to displace any non-specific uptake of 3H-thymidine. Cells were
then washed in PBS and cellular proteins precipitated with cold
5% trichloroacetic acid. After removing the liquid layer, an aliquot
of 0.1 M sodium hydroxide was added to the cells, and radio-
activity in the resulting solubilized nuclear material was deter-
mined by scintillation counting. Data were reported as mean ±
standard deviation of radioactive counts per minute (cpm) (n = 4).
Analysis of 17β-HSD isozyme mRNA expression
RNA extraction and RT-PCR analysis
Total RNA was extracted from cultured cells using RNazol (AMS
Biotechnology, Witney, UK), according to an adapted guani-
dinium-isothiocyanate method (Hughes et al 1997). Reverse
transcription of RNA was performed using a Promega Reverse
Transcription System (Promega Corp., Madison, WI) using previ-
ously reported methods (Hughes et al 1997). PCR analysis of 17β-
HSD mRNA expression was carried out using the following
primers for 17β-HSD types 1 to 4: 17β-HSD1: (5′ primer) 5′ AGG
CTT ATG CGA GAG TCT GG3′; (3′ primer) 5′ CAT GGC GGT
GAC GTA GTT GG3′ (bp 1460–1809); 17β-HSD2: 5′ CTG AGG
AAT TGC GAA GAA CC3′, 5′ GAA GTC CTT GCT GGC TAA
CG3′ (bp 445–1038); 17β-HSD3: 5′ ACA ATG TCG GAA
TGC3′, 5′ AGG TTG AAG TGC TGG TCT TCT GC3′ (bp
437–1051); 17β-HSD4: 5′ CTA TTG GCC AGA AACTCC CT3′;
5′ GGA CCT TGG TTT GAA AAT GA3′ (bp 1028–1819). PCR
reactions were set up in PCR buffer containing 50 mM KCl, 
10 mM Tris-HCl (pH 9.0) and 0.1% Triton X-100, 1.5 mM MgCl2,
0.2 µM of each dNTP, 0.5 µM (17β-HSD1, 2 and 3) or 0.4 µM
(17β-HSD4) of primers and 1 µ of Taq DNA polymerase.
Amplification of cDNA was performed using an initial denatura-
tion step of 95°C followed by either 30 cycles of 95°C (1 min);
60°C (1 min); 72°C (1 min)(17β-HSD1–3) or 30 cycles of 95°C 
(1 min); 55°C (1 min); 72°C (1 min)(17β-HSD4). A final elonga-
tion step of 72°C for 7 minutes was also included.
Northern blot analysis of 17β-HSD expression
Northern blot analysis of 17β-HSD mRNA expression was carried
out using aliquots (10 µg) of total RNA from each cell line. RNA
was separated by denaturing gel electrophoresis and blotted onto
Hybond N nylon filters (Amersham). After fixation by UV irradia-
tion, filters were probed using previously reported methods
(Hughes et al, 1997), and then exposed to Dupont Cronex film
(Dupont/NEN, Boston) for various time periods, before develop-
ment of autoradiographs.
Western blot analysis
Colonic mucosae, tumour tissue and cell lines were homogenized
in the presence of the protease inhibitor PMSF (Sigma) (0.5 mM)
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and then centrifuged at 4°C and 6500 rpm for 5 min. Aliquots of
the resulting supernatants, corresponding to cytoplasmic prepara-
tions, were then denatured at 95°C in 2% SDS, 10% glycerol, 
62.5 mM Tris (pH 6.8) and size-separated on 10% SDS-PAGE
gels. Proteins were transferred to Immobilon P membrane (0.4
µm; Millipore Corp, Bedford, MA). The resulting membranes
were blocked by incubating overnight in PBS containing 10%
bovine serum albumin (Sigma). Immunoreactivity was detected by
incubation with primary antibody (17β-HSD2 diluted 1:100; 
17β-HSD4 diluted 1:200) followed by peroxidase-conjugated anti-
mouse secondary antibody (Amersham). The reaction detected by
enhanced chemiluminescence (ECL, Amersham Pharmacia
Biotech, Buckinghamshire, UK). The sizes of the reactive
immunoproteins were estimated by comparison to the mobility of
protein standards (Amersham).
Data analysis
Immunohistochemistry and Western blot analyses were carried out
using paired normal and tumour samples (n = 3). Immuno-
histochemistry data were shown as a single pair of representative
sections. Assays for 17β-HSD activity were carried out in tripli-
cate and cell proliferation assays in quadruplicate. Data from both
were reported as mean ± standard deviation (SD). Figures show
typical experiments that were successfully repeated at least three
times. Statistical calculations were performed using one-way
analysis of variance (ANOVA) with the statistical software
package Sigma-Stat3 (Jandel Scientific, Germany).
ΡΕΣΥΛΤΣ
Expression of 17β-HSD2 and 4 in the colon
Immunocytochemical analysis of proteins for 17β-HSD2 and 4 in
human tissue was carried out using colon sections as well as posi-
tive and negative control tissues (Figure 1). Analysis of positive
control tissue (placenta) showed expression of 17β-HSD2 in
stromal cells but not syncytiotrophoblasts, while 17β-HSD4 was
detectable in both stromal and trophoblastic cells (Figure 1A and
1D). No staining was detected for either isozyme in testis (data not
shown). In the colon, 17β-HSD2 and 4 were found mainly in
colonic epithelial cells with increased immunoreactivity towards
the luminal surface (Figure 1D and 1E). In contrast to normal
colonic epithelium, expression of 17β-HSD2 and 4 was relatively
weak in colonic mucosae adjacent to a tumour, and weaker still in
tumour tissue itself (Figure 1C and 1F).
Western blot analysis of 17β-HSD2 and 4 indicated that the
pattern of protein expression for these isozymes was different in
tumour biopsies when compared to paired normal mucosal tissue
(Figure 2). In normal mucosae and positive control tissue
(placenta), 17β-HSD2 was expressed as a single protein species of
45 kDa. However, in each of the paired tumour samples an addi-
tional band of approximately 50 kDa was also detected. Similar
data were obtained following Western analysis of 17β-HSD4
(Figure 3). In control tissue (placenta) and normal colonic
mucosae a single protein species of 32 kDa was detected, with an
additional band of approximately 46 kDa in tumour specimens.
Statistical analysis showed no significant difference in expression
between normal and tumour tissue for both 17β-HSD2 and 17β-
HSD4 (P = 0.386 and 0.318 respectively).
Analysis of 17β-HSD activity in vitro
Further analysis of the expression and regulation of 17β-HSD2
and 4 in colonic epithelial cells was carried out using three colonic
cancer cell lines. Initial enzyme activity studies revealed a similar
pattern of oestrogen metabolism to that previously described in
primary colonic mucosae (English et al, 1999). In Caco-2, SW620
and HT-29 cells the predominant 17β-HSD activity was oxidative
conversion of E2 to E1. Using 50 nM E2 as substrate the highest
activity was observed in Caco-2 cells (52 ± 5.0 pmoles h–1 mg
protein–1, followed by SW620 cells (23 ± 2.0 pmoles h–1 mg
protein–1), and HT-29 cells (8 ± 1 pmoles h–1 mg protein–1). Kinetic
analysis of 17β-HSD activity in SW620 cells indicated that the
affinity constant (K
m
) was 400 nM E2, with a maximal enzyme
activity (V
max
) of 190 pmoles E1 h–1 mg protein–1. Further enzyme
assays using lysates from SW620 cells demonstrated that the
conversion of E2 to E1 in these cells was dependent upon NAD+ as
a co-factor (data not shown). Reductive activity (conversion of E1
to E2) was highest in Caco-2 cells (8.4 ± 3.8 pmoles hr–1 mg
protein–1), followed by HT-29 (4.1 ± 2.3 pmoles hr–1 mg protein–1)
and SW620 (2.5 ± 1.1 pmoles hr–1 mg protein–1).
All three cell lines were used in further studies to investigate the
regulation of E2 inactivation in colonic cells. Cells were incubated
for 24 hours in charcoal-stripped, phenol red-free medium in the
presence of various steroid hormones (all at 100 nM). Data shown
in Figure 3 indicated that, following 24 h treatments, only 1,25D3
and E2 itself were able to modulate 17β-HSD activity. In Caco-2
and SW620, E2 significantly inhibited oxidative 17β-HSD activity.
In contrast, in SW620 and HT-29 cells, 1,25D3 potently stimulated
17β-HSD activity. Caco-2 cells showed a similar trend which was
not statistically significant at this time point. Further studies were
carried out to investigate these responses in more detail and
compare changes in 17β-HSD activity with effects on colonic cell
proliferation. Dose–response experiments using SW620 cells
confirmed the sensitive up-regulation of oxidative 17β-HSD
activity by 1,25D3, as well as the inhibitory effects of E2 (Figure
4). However, it was noted that low doses (1 nM) of E1 and testos-
terone (T) also produced a significant decrease in 17β-HSD
activity. Although these effects were observed after 24 hours, we
were unable to detect any significant changes in cell proliferation
until 72 hours of treatment; at this time point antiproliferative
effects were observed following treatment with 1,25D3 or E1
(Figure 4). Similar observations were also made using Caco-2
cells, and in both cell lines none of the treatments had a significant
effect on reductive 17β-HSD activity (E1 to E2 conversion) (data
not shown).
17β-HSD isozyme expression in colonic cancer cells
RT-PCR analyses indicated that transcripts for 17β-HSD1–4 were
detectable in all three cell lines (Figure 5A). However, Northern
blots probed with purified cDNAs generated by RT-PCR
confirmed the presence of mRNA for 17β-HSD2 and 4, but not
17β-HSD1 and 3. Data in Figure 5B show Northern blot analyses
of 17β-HSD2 and 4 mRNA expression in SW620 cells. Single
transcripts corresponding to the reported mRNA species for 17β-
HSD2 (1.3 kb) and 17β-HSD4 (3.0 kb) were detected. The expres-
sion of mRNA for both isozymes was inhibited by 24 hour treat-
ment with 1,25D3, E1 and E2 but not progesterone (all at 100 nM).
Further analysis of the effects of 1,25D3 indicated that lower doses
of the hormone (1 nM and 10 nM) also down-regulated mRNA
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levels for 17β-HSD2 and 4 (data not shown). The effects of 1,25D3
on expression of 17β-HSD2 and 4 were studied further using
Western blots and isozyme-specific antibodies. Data in Figure 6
show that proteins corresponding to both isozymes were readily
detectable in SW620 cells. In untreated cells two principal species
were detected for 17β-HSD2 and 4. In each case the smallest
protein band (45 kDa for 17β-HSD2, 32 kDa for 17β-HSD4)
corresponded to the reported size of each isozyme. However, a
larger species (approximately 50 kDa for 17β-HSD2, 46 kDa for
17β-HSD4) was also observed which was not present in positive
control tissue (placenta). Treatment with 1,25D3 (1–100 nM) for
24 h did not appear to have any effect on the expression of the
protein species for either 17β-HSD2 or 4.
DΙΣΧΥΣΣΙΟΝ
Sex hormones play a key role in the pathophysiology of some
cancers. In particular, oestrogen has been shown to play a major
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Figure 1 Immunolocalization of 17β-HSD2 (A–C) and 17β-HSD4 (D–F) in: (A and D) placenta (positive control) (× 100); (B and E) colon surface epithelial cell
layer (× 100); (C and F) colonic mucosa adjacent to a tumour (left) and colonic tumour tissue (right) (× 100). Positive staining (brown) is observed in colonic
epithelial cells. Sections were counterstained with Mayer’s haematoxylin
role in the development, progression and treatment of breast cancer
(Colditz, 1998; Osborne, 1998). This has led to the use of synthetic
receptor agonists such as tamoxifen as a treatment regime for ER-
positive breast tumours (McDonnell, 1999). However, another
approach to this type of therapy has been to regulate ER responses
by modulating the availability of endogenous ER ligand within
tumour tissue. Local synthesis of oestrogens as a result of endoge-
neous aromatase, 17β-HSD and oestrone sulphatase activity has
been demonstrated in endometrial (Maentausta et al, 1992),
prostate (Elo et al, 1996) and breast tumours (Pasqualini et al,
1996). As a consequence, novel anti-cancer therapies have been
aimed at controlling the local build-up of oestrogens in tumours by
inhibiting the activity of specific steroidogenic enzymes, particu-
larly aromatase and oestrone sulphatase (Brodie et al, 1999).
Epidemiological evidence suggests that the incidence of colonic
cancer is also influenced by sex hormones (Langman, 1967;
Michael and Potter, 1982; Calle et al, 1995; Newcomb and Storer,
1995; Persson et al, 1996). In common with breast cancer, normal
and neoplastic colonic mucosae show differential responses to E2,
although this does not appear to be due to dysregulation of ER
expression (Singh et al, 1994, 1998).
In more recent studies we have postulated that enhanced
oestrogen responsiveness in colonic tumours may be due to
decreased inactivation of E2 by isozymes of 17β-HSD (English et
al, 1999). Immunohistochemical data presented here indicate that
17β-HSD2 and 4 are localized predominantly within the luminal
surface of the normal colonic epithelium, supporting previous
reports of 17β-HSD2 expression in the gastrointestinal epithelium
of the mouse (Mustonen et al, 1998), and human fetus (Takeyama
et al, 2000). It would therefore appear that oestrogen inactivation
by locally expressed 17β-HSD isozymes is a feature of normal
gastrointestinal biology. The most likely function of these
isozymes within colonic epithelial cells is that they form part of a
mechanism that protects the colon against environmental or bacte-
rially-synthesized steroids. In recent studies, 17β-HSD2 has been
shown to metabolize several orally administered steroidal
compounds, including those used in oral contraceptives and HRT
(Puranen et al, 1999). It was also interesting to note the presence of
17β-HSD2 and 4 in colonic crypts. Pluripotent stem cells occur in
the crypt base and daughter cells migrate upwards undergoing a
series of divisions before full maturation. In view of the mitogenic
nature of E2 this suggests that 17β-HSD2 and 4 may also play a
role in modulating epithelial cell development.
Western blot analysis of normal colon of biopsy specimens
confirmed the specificity of the 17β-HSD antisera used for
immunohistochemistry studies. However, in tumour material and
colonic cancer cell lines, additional larger protein species for 17β-
HSD2 and 17β-HSD4 were also detected. Previous studies of 17β-
HSD expression in breast cancer tissue, indicated the presence of
enzymes with molecular weights in the range of 50–80 kDa in
addition to a 35 kDa enzyme with different properties from those
of the 35 kDa enzyme with the same molecular weight in adipose
tissue (Mann et al, 1999). To date no similar studies have been
carried out on colonic cancer tissue. However, it is possible to
speculate that the presence of tumour-specific hydroxysteroid
dehydrogenase proteins may alter co-factor availability, or result
in the quenching of specific substrates. This may help to explain
the decreased capacity for oestrogen inactivation that we have
described previously in colonic tumours (English et al, 1999). It is
also important to note that 17β-HSD4 is a 80 kDa multi-domain
protein, which has previously been reported to undergo processing
to the 32 kDa protein detected in target tissues. Evidence for
further processing into additional fragments has been demon-
strated in rat tissue by peroxisome proliferator chemicals (Fan et
al, 1998). Tumour specific processing of this particular isozyme
may therefore occur by an as yet unidentified mechanism,
resulting in species that competitively alter oestrogen inactivation.
Experiments in vitro confirmed that the overall pattern of
oestrogen metabolism in these cells was similar to that observed
with primary human colonic tissue, namely 17β-HSD-mediated
inactivation of E2 to E1. Levels of E2 metabolism varied between
the cell lines but only the antiproliferative agent 1,25D3 and E1 and
E2 had any significant effect on enzyme activity. E2-mediated
regulation of oxidative 17β-HSD activity has not previously been
reported in other tumour tissues although, in breast cancer cells, E1
has been shown to significantly inhibit 17β-HSD activity (Mehta
and Gupta, 1993; Peltoketo et al, 1996). The decreased 17β-HSD
activity observed following treatment of Caco-2 and SW620 cells
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Figure 2 Representative Western blot analysis of 17β-HSD2 and 4
expression in n = 3 paired samples of normal human colonic mucosae and
colonic tumours. The position of molecular weight markers is shown on the
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Figure 3 Effect of steroid hormones on 17β-HSD activity in colonic cancer
cells. Caco-2, SW-620 and HT29 cells were grown in phenol red-free
medium +5% FCS until 80% confluent, and then for a further 24 hours in
phenol red-free medium +5% charcoal-stripped FCS in the presence of:
oestrone (E1), oestradiol (E2), dexamethasone (DEX), dihydrotestosterone(DHT), testosterone (T), progesterone (Prg), and 1,25-dihydroxyvitamin D3(1,25D3) (all at 100 nM). Oxidative 17β-HSD activity was assessed using 
100 nM [3H]-E2 as substrate. Data shown are means ± SD (n = 3). * = signifi-
cantly different from control cells, P < 0.05;** = significantly different from
control cells, P < 0.01; *** = significantly different from control cells, P < 0.001
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Figure 4 Effects of steroid hormones on 17β-HSD activity and cell proliferation in SW-620 cells. Cell were treated with 1–100 nM concentrations of oestradiol
(E2), oestrone (E1), testosterone (T), progesterone (Prg), or 1,25-dihydroxyvitamin D3 (1,25D3) for either 24 hours (17β-HSD activity) or 72 hours (cell
proliferation). Data shown are means ± SD (n = 3 for 17β-HSD activity, n = 4 for 3H-thymidine). *= significantly different from control cells, P < 0.05;
** = significantly different from control cells, P < 0.01
with E2 and E1 correlated with decreased expression of mRNAs for
both 17β-HSD2 and 4. In contrast, although 1,25D3 also down-
regulated the expression of mRNAs for 17β-HSD2 and 4, its
overall effect on enzyme activity in HT-29 and SW620 cells was to
stimulate E2 inactivation. It therefore seems likely that there are
different mechanisms involved in regulating oestrogen metabo-
lism in colonic cells. The effect of E1 and E2 appears to be due to
direct inhibition of 17β-HSD transcription. In contrast, responses
to 1,25D3 were similar to those we have previously described for
HL60 leukaemic cells and normal human keratinocytes; treatment
with 1,25D3 produced a similar rapid induction of E2 inactivation
that was also associated with decreased 17β-HSD4 mRNA expres-
sion (Hughes et al, 1997; Mountford et al, 1999). These observa-
tions, together with the Western analyses presented here suggest
that the stimulation of oestrogen metabolism by 1,25D3 in colonic
cancer cells may not be mediated via direct regulation of 17β-
HSD2 or 4. Rather it is possible that the 1,25D3-induced stimula-
tion of E2 inactivation is due to indirect stimulation of another
17β-HSD isozyme, possibly as a result of a shift in the availability
of enzyme co-factors such as NAD+. The contribution of other
17β-HSD isozymes to cell proliferation and differentiation
remains unclear. The type 1, 3, 5 and 7 isozymes show predomi-
nantly reductive (E1 and E2) activity and are therefore unlikely
candidates, particularly as we were unable to demonstrate signifi-
cant amounts of mRNA for 17β-HSD1 and 3 in colonic mucosae
and cancer cell lines. However, conversion of E1 to E2 was
detectable in these samples. Although this was relatively low
compared to oxidative activity (E2 to E1 conversion) the possibility
remains that a variety of 17β-HSD enzyme activities are found in
the colon, including possible novel isozymes of 17β-HSD.
In previous reports we have postulated that decreased E2 inacti-
vation may make a significant contribution to the enhanced cell
proliferation associated with colonic tumours (English et al, 1999).
Here we have shown that the antiproliferative effects of 1,25D3
are preceeded by sensitive up-regulation of E2 inactivation. In
contrast, known mitogenic agents such as E2 demonstrated
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Figure 5 Expression of mRNA for 17β-HSD isozymes in colonic cancer cells. (A) RT-PCR analysis of 17β-HSD isozyme expression in Caco-2, SW620 and
HT29 cells. Positive control RNAs included placenta (17β-HSD1, 2 and 4) and testis (17β-HSD3). (B) Northern analysis of 17β-HSD2 and 4 expression in
SW620 cells treated with oestradiol (E2), oestrone (E1), progesterone (Prg), or 1,25-dihydroxyvitamin D3 (1,25D3) for 24 hours (all at 100 nM). Blots were probed
with radiolabelled PCR fragments generated from the studies shown in 4A
17β-HSD 1
17β-HSD 4
46 kDa
46 kDa
C 0.1 1 10
Figure 6 Western blot analysis of 17β-HSD2 and 4 expression in SW-620
cells. Changes in the expression of proteins for 17β-HSD2 and 4 were
assessed following treatment with oestradiol (E2), oestrone (E1),
progesterone (Prg), or 1,25-dihydroxyvitamin D3 (1,25D3) for 24 hours (all at
100 nM). The position of molecular weight markers is indicated on the right
apparent autocrine inhibition of 17β-HSD activity. Similar inhibi-
tion of E2 inactivation was also observed with low doses of E1 or T,
although the precise mechanism for this remains unclear. Other
groups have demonstrated pro-proliferative responses to E2 in
colonic cells lines (Xu and Thomas, 1994; Di Domenico et al,
1996). Although we were unable to confirm this effect of E2 in our
models systems, it was interesting to note that treatment with E1 at
concentrations of 100 nM or greater significantly inhibited cell
proliferation. These data support previous studies in which we
have shown that generation of E1 through the action of 17β-HSD
isozymes may act as a novel component of cell differentiation
processes (Hughes et al, 1997; Mountford et al, 1999). Thus, stim-
ulation of 17β-HSD activity by established differentiating agents
may not only decrease the availability of mitogenic E2 but could
also enhance local concentrations of antiproliferative E1.
A putative role for E1 as a novel antiproliferative agent may help
to resolve the paradox associated with the epidemiology of oestro-
gens and colon cancer. On the one hand an increased ratio of
circulating E1/E2 in postmenopausal women is associated with
decreased risk of colon cancer. Conversely, HRT has also been
shown to protect against colon cancer. A clear relationship
between the composition of HRT and effects on colon cancer has
yet to be fully described. However, it is important to recognize that
the principal prescribed HRTs (Premarin/Prempak C) contain
delta-8-E1 sulphate rather than E2. Consequently, within the colon,
the most likely metabolite that will be derived from this treatment
is E1 and not E2. Importantly, the immunohistochemistry data
presented here indicate that orally administered HRT regimes that
contain E2 may lead to the generation of increased local levels of
E1 in the colon. The discrete expression of 17β-HSD2 and 4 in the
epithelial cells of the colonic mucosa provides an efficient barrier
for inactivation of ingested steroids including the E2 present in
some oral HRT regimes. Other components of HRT preparations
such as progesterone appeared to be without effect in terms of 17β-
HSD expression/activity, or cell proliferation. It is possible that
progesterone itself may be subject to local metabolism but as yet
the potential effects of this on colonic cells remain unclear.
In summary we have presented further evidence for the impor-
tant role of 17β-HSD isozymes as modulators of oestrogen
effects in the colon. Localization of 17β-HSD2 and 4 to the
epithelial layer of the colon and the presence of these isozymes
in epithelial cell lines highlights a potential role as protective
barrier against ingested oestrogens. In addition, regulatory
studies have confirmed the association between colonic cell
proliferation and 17β-HSD activity, further emphasizing the
possible importance of E2 inactivation in the aetiology of colon
cancer. Further studies to define the cellular impact of HRT, and
to identify other 17β-HSD isozymes in the colon will help to
clarify the role of hormone metabolism in colonic cell develop-
ment, but may also provide a novel target for improved therapies
for colonic cancer.
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